Schizophrenia proteomics biomarkers on the path to laboratory medicine 英文参考文献.docVIP

Diagnostic Pathology BioMedCentral Review Open Access Schizophrenia proteomics: biomarkers on the path to laboratory medicine? Shaheen Emmanuel Lakhan* Address: Global Neuroscience Initiative Foundation, Los Angeles, CA, USA Email: Shaheen Emmanuel Lakhan* - slakhan@ * Corresponding author Published: 17 July 2006 Received: 28 June 2006 Accepted: 17 July 2006 Diagnostic Pathology 2006, 1:11 doi:10.1186/1746-1596-1-11 This article is available from: /content/1/1/11 ? 2006 Lakhan; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Over two million Americans are afflicted with schizophrenia, a debilitating mental health disorder with a unique symptomatic and epidemiological profile. Genomics studies have hinted towards candidate schizophrenia susceptibility chromosomal loci and genes. Modern proteomic tools, particularly mass spectrometry and expression scanning, aim to identify both pathogenic-revealing and diagnostically significant biomarkers. Only a few studies on basic proteomics have been conducted for psychiatric disorders relative to the plethora of cancer specific experiments. One such proteomic utility enables the discovery of proteins and biological marker fingerprinting profiling techniques (SELDI-TOF-MS), and then subjects them to tandem mass spectrometric fragmentation and de novo protein sequencing (MALDI-TOF/TOF-MS) for the accurate identification and characterization of the proteins. Such utilities can explain the pathogenesis of neuro-psychiatric disease, provide more objective testing methods, and further demonstrate a biological basis to mental illness. Although clinical proteomics in schizophrenia have yet to re